Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 230 PARK AVENUE, SUITE 3350 NEW YORK NY 10169 |
Tel: | N/A |
Website: | https://www.ymabs.com |
IR: | See website |
Key People | ||
Michael Rossi President, Chief Executive Officer, Director | Thomas Gad Vice Chairman of the Board, Chief Business Officer | Bo Kruse Chief Financial Officer, Executive Vice President, Treasurer, Secretary |
Joris Wiel Jan Wilms Chief Operating Officer, Senior Vice President | Torben Lund-Hansen Senior Vice President, Chief Technical Officer | Steen Lisby Senior Vice President, Chief Scientific Officer |
Vignesh Rajah Senior Vice President, Chief Medical Officer | Susan Smith Senior Vice President, Chief Commercial Officer |
Business Overview |
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types. |
Financial Overview |
For the three months ended 31 March 2024, Y-mAbs Therapeutics Inc revenues decreased 2% to $19.9M. Net loss increased 4% to $6.6M. Revenues reflect License revenue decrease of 4% to $19.4M. Higher net loss reflects Research and development - Balancing val increase from $1.7M to $9.4M (expense), General and administrative - Balancing increase of 41% to $11.3M (expense), Interest and other income decrease of 60% to $439K (income). |